Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06984328 · ClinicalTrials.gov registry record · Phase 2

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

A Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), sponsored by Genmab.

Active
Registry status
Phase 2
Development phase
1
Enrollment target
2
Study locations

NCT06984328 is a Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) that is active but no longer recruiting, run by Genmab. The registered enrollment target is 1 participants, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06984328, a Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), is active but no longer recruiting, sponsored by Genmab.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
1 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. The trial duration will be approximately 15 months for each participant, including a 28-day screening period and estimated 4-month treatment and 10-month follow-up periods; however, the duration of the treatment and follow-up periods may vary for each participant. Participants will have regular check-ups while on treatment, with visits every week initially, and then every 3 weeks later in the trial.

Conditions Studied

Cutaneous Melanoma Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) Metastatic Cutaneous Melanoma (Stage IV)

Interventions

  • BIOLOGICAL Pembrolizumab
  • BIOLOGICAL Acasunlimab

Study Locations (2)

Tennessee

  • Tennessee Oncology, PLLC - Nashville

Other

  • Pan American Center for Oncology Trials, LLC - San Juan

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2025-07-25
Est. Completion 2029-07-15
Phase Phase 2

Sponsor

Genmab

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06984328

The ClinicalTrials.gov registry entry for NCT06984328 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (100% lower). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06984328 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Other.

Frequently Asked Questions

What is clinical trial NCT06984328 about?

NCT06984328 is a clinical study titled "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)". The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. ...

What is the current status of trial NCT06984328?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2025-07-25. Estimated completion is 2029-07-15.

What conditions does trial NCT06984328 study?

This clinical trial studies the following conditions: Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV).

What interventions are being tested in trial NCT06984328?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Acasunlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06984328?

This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06984328 being conducted?

This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cutaneous Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cutaneous Melanoma

All registered trials for this condition

Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.